The thyroid axis is a key modulator of both energy balance and lipid metabolism [1] [2] [3] . Hyperthyroidism is a clinical disorder characterized by excessive production of thyroid hormones (T3 and tetraiodothyronine (T4)), which causes a hypermetabolic state characterized by increased energy expenditure and weight loss despite marked hyperphagia 3, 4 . Although it is generally assumed that most effects of thyroid hormones on energy homeostasis are exerted in peripheral tissues 1, 3, 5 , recent evidence indicates that hypothalamic neurons sense nutritional deficits through a mechanism that involves local generation of T3, leading to the induction of uncoupling protein-2 (ref. 2).
a r t i c l e s 1 0 0 2 VOLUME 16 | NUMBER 9 | SEPTEMBER 2010 nature medicine stimulating hormone) and reduced thyrotropin-releasing hormone (Trh) expression in the paraventricular nucleus of the hypothalamus (PVH) (Supplementary Table 1 ). T4-treated rats gained considerably less weight than vehicle-treated rats on a normal chow diet ( Supplementary Fig. 1a ), despite marked hyperphagia ( Supplementary  Fig. 1b) . Analysis of fat pads showed that T4 treatment decreased WAT and increased BAT mass compared with euthyroid rats ( Supplementary  Fig. 1c and Supplementary Table 1) . Diiodothyronine (T2), an inactive thyroid hormone metabolite, did not change either body weight or food intake (data not shown). Consistent with the hyperphagic state, mRNA expression of agoutirelated protein (Agrp) and neuropeptide Y (Npy) increased, and proopiomelanocortin (Pomc) decreased, in the arcuate nucleus of the hypothalamus of hyperthyroid rats (Supplementary Fig. 1d ).
Hyperthyroidism inhibits the hypothalamic AMPK pathway Hyperthyroid rats, but not rats treated with T2 (data not shown), showed a marked decrease in phosphorylation of hypothalamic AMPKα (pAMPKα) and ACCα (pACCα) associated with a decrease in the concentration and activity of AMPKα1 (Fig. 1a) . Our data also revealed a marked increase in FAS protein concentration (Fig. 1a) , expression of mRNA for FAS (encoded by Fasn) (Fig. 1b and Supplementary Fig. 1e ) and the concentration of malonyl-CoA (Fig. 1c) in the hypothalamus of hyperthyroid rats, accompanied by a reduction in carnitine palmitoyltransferase-1 (CPT1) activity (Fig. 1d) . Food restriction lowered malonyl-CoA concentration in the hypothalamus of euthyroid rats but had no effect in hyperthyroid rats (Supplementary Fig. 1f ). Hyperthyroidism did not alter the AMPK pathway in the cerebral cortex (Supplementary Fig. 2a) , indicating that thyroid hormone excess specifically activates the early stages of fatty acid lipogenesis in the hypothalamus. By using a lipidomic approach, we also saw increased accumulation of complex lipid species specifically in the hypothalamus of hyperthyroid rats (data not shown). As in the hypothalamus, hyperthyroidism decreased AMPK amounts in the liver but increases them in the muscle and WAT (Supplementary Fig. 2b-d) .
We also analyzed the effect of hypothyroidism induced in rats by 3-week treatment with aminotriazole, which decreased plasma concentrations of T4 and T3, increased plasma thyrotropin concentrations and increased Trh expression in the PVH (Supplementary Table 1 ). Hypothyroidism increased AMPKα1 amounts and activity in the hypothalamus (Supplementary Fig. 2e,f) and markedly decreased FAS concentration in the liver (Supplementary Fig. 2g ). AMPK was inhibited in the muscle and WAT of hypothyroid rats ( Supplementary Fig. 2h,i) .
Hyperthyroid rats do not respond to central FAS inhibition
Increased concentration of hypothalamic malonyl-CoA, determined by the balance between ACC and FAS activities, inhibits food intake 17, [19] [20] [21] [22] 26, 27 . Our data showed that hyperthyroid rats were hyperphagic despite a higher concentration of malonylCoA in the hypothalamus than that in euthyroid rats. We therefore tested whether further increasing malonyl-CoA abundance by inhibiting FAS 21, 26, 27 would reverse hyperphagia in hyperthyroid rats. To evaluate this, we centrally treated hyperthyroid rats with the FAS inhibitor cerulenin for 4 d. This treatment did not alter E u t h y r o id H y p e r t h y r o id E u t h y r o id H y p e r t h y r o id E u t h y r o id H y p e r t h y r o id E u t h y r o id H y p e r t h y r o id E u t h y r o id H y p e r t h y r o id E u t h y r o id body weight (Fig. 1e) or food intake ( Fig. 1f and Supplementary  Fig. 3a ) in hyperthyroid rats, despite a marked additional increase in hypothalamic malonyl-CoA amounts (Fig. 1g) . In contrast, in euthyroid rats, the same dose of cerulenin increased malonyl-CoA to levels comparable to those in hyperthyroid rats, accompanied by marked anorexia and weight loss (Fig. 1e-g and Supplementary Fig. 3a) .
We observed no change in the expression of either agouti-related protein (Agrp) or neuropeptide Y (Npy) mRNA in the arcuate nucleus of the hypothalamus after cerulenin treatment ( Supplementary  Fig. 3b,c) . However, cerulenin induced a marked increase in Pomc mRNA in euthyroid but not hyperthyroid rats ( Fig. 1h and Supplementary Fig. 3d ), which might account for the anorexic effects of this drug in euthyroid rats. The increase in Pomc expression was accompanied by parallel changes in the concentration of phosphoforkhead box O1 (pFoxO1) and phospho-signal transducer and activator of transcription-3 (pSTAT3) (Fig. 1i) .
Central T3 increases BAT thermogenesis through 3 adrenoceptors Chronic intracerebroventricular (i.c.v.) treatment with T3 markedly reduced body weight (Fig. 2a,b) without altering food intake (Fig. 2c,d ) in euthyroid and hypothyroid rats. Such treatment decreased phosphorylation of hypothalamic AMPK and ACC (Fig. 2e) . It also increased the expression of thermogenic markers, such as uncoupling protein-1 (Ucp1) and UCP3 (Ucp3), peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α, encoded by Ppargc1a), fatty acid-binding protein-3 (Fabp3), hormonesensitive lipase (encoded by Lipe), lipoprotein lipase (Lpl) and type 2 deiodinase (encoded by Dio2) in the BAT of euthyroid rats (Fig. 2f) , but not in other peripheral organs, such as liver and muscle ( Supplementary Fig. 4a,b) . Chronic i.c.v. treatment with T3 also increased Ucp1, Ucp3, Dio2 and Fabp3 expression in the BAT of hypothyroid rats but did not have major effects in other thermogenic markers either in liver or muscle ( Supplementary  Fig. 4c-e) . Furthermore, i.c.v. administration of T3 did not alter plasma T3 or T4 concentration (data not shown). As a control to rule out that i.c.v. administered T3 was leaking into the periphery and having direct effects on peripheral tissue, we found no changes in body weight, food intake, the hypothalamic AMPK pathway protein concentrations or the thermogenic program in BAT after intraperitoneal administration of T3 at the dose administered i.c.v. (Supplementary Fig. 4f-i) .
In rodents, SNS stimulation activates β3 adrenoceptors (β3-AR, encoded by Adrb3) on brown adipocytes 5, 29 . Pharmacological antagonism of β3-AR by subcutaneous administration of the specific antagonist SR59230A 30 prevented the reduction in body weight associated with central administration of T3 ( Fig. 2g) without changing food intake (Fig. 2h) . In keeping with these observations, SR59230A blocked central T3 induction of the thermogenic program in BAT (Fig. 2i) . 
P p a r g c 1 b
treated with the β3-AR-specific antagonist SR59230A for 4 d. ! P = 0.09, $ P = 0.08, + P = 0.06, *P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle; # P < 0.05, ## P < 0.01 T3 i.c.v. versus T3 i.c.v. SR59230A; all data are expressed as means ± s.e.m. Central T3 activates the SNS that signals to the BAT Colocalization studies of pAMPKα and thyroid hormone receptor-(TRα) TRα showed that pAMPKα is widely expressed in the hypothalamus, with high amounts in the arcuate nucleus, PVH and VMH ( Supplementary Fig. 5a-c) , and that there is a high degree of colocalization of pAMPKα and TRα in the VMH (Fig. 3a) . When we injected T3 i.c.v., it exerted a robust and rapid (within 1 h) reduction in pAMPK and pACC abundance in the hypothalamus (Fig. 3b) , accompanied by an increase in c-Fos immunoreactivity, a marker of neuronal activation 26, 31 , in the raphe pallidus and the inferior olive nuclei and in the dorsal motor nucleus of the vagus. Notably, all of these nuclei receive neuronal projections from the VMH 5, 31 ( Fig. 3c) . This central effect of T3 was associated with a dose-dependent increase in activity of the SNS that signals to the BAT (Fig. 3d,e) . Of note, we detected no changes in feeding after acute i.c.v. treatment with T3 (Supplementary Fig. 5d ). Stereotaxic administration of T3 to the VMH (Supplementary Fig. 5e ) caused a rapid (within 1 h) effect, decreasing both pAMPK and pACC in this area (Fig. 3f) , accompanied by increased BAT sympathetic nerve activity (SNA) (Fig. 3g) . Acute VMH treatment with T3 did not induce changes in food intake (Supplementary Fig. 5f ).
Central T3 is essential for BAT thermogenic program
We then ablated TR action in the VMH of hyperthyroid rats with an adenovirus encoding a dominant-negative TR (TR-DN) 32 , as previously described 19 ( Supplementary Fig. 6a-c) . TR-DN adenovirus prevented T3-dependent activation of a thyroid response element-driven reporter gene and inhibited induction of the gene encoding sex hormone binding globulin (Shbg), a known target gene, in HepG2 cells (Supplementary Fig. 6d-f) .
Injecting TR-DN into the VMH of hyperthyroid rats blunted weight loss (Fig. 4a) , did not alter either feeding (Fig. 4b) or circulating concentrations of T3 and T4 (Fig. 4c,d ) and decreased expression of thermogenic markers in BAT (Fig. 4e) . Similar treatment in euthyroid rats was without effect (Supplementary Fig. 6g-j) .
AMPK in the VMH modulates BAT thermogenesis via the SNS
We next investigated whether inactivation of hypothalamic de novo lipogenesis, would affect the expression of thermogenic markers in the BAT. I.c.v. administration of the ACC inhibitor TOFA (5-(tetradecyloxy)-2-furoic acid) did not alter body weight in euthyroid rats; however, it reversed weight loss in hyperthyroid rats without changes in feeding (Fig. 5a) . The increase in body weight induced by TOFA was associated with decreased amounts of hypothalamic malonyl-CoA (Fig. 5b) and decreased mRNA expression of Ucp1 and Ucp3 in BAT (Fig. 5c) .When we i.c.v. administered the AMPK activator AICAR (5-aminoimidazole-4-carboxamide-1-d-ribofuranoside) it showed similar effects on body weight, food intake ( Fig. 5d) , malonyl-CoA (Fig. 5e) and Ucp1 and Ucp3 expression in BAT (Fig. 5f) . Adenoviruses encoding constitutively active AMPKα (AMPKα-CA) 16 were injected stereotaxically into the VMH of hyperthyroid rats as described above. AMPKα-CA lowered malonyl-CoA abundance in the ventral hypothalamus (Fig. 5g) , which was associated with weight gain in hyperthyroid but not euthyroid rats ( Fig. 5h and Supplementary Fig. 7a ), although there was no alteration in food intake ( Fig. 5h and Supplementary Fig. 7b ). Overexpression of AMPKα-CA in the VMH was associated with a specific reduction in the expression of BAT thermogenic markers in hyperthyroid (Fig. 5i) but not euthyroid (Supplementary Fig. 7c,d ) rats.
To assess the role of AMPKα in the regulation of energy balance, we inactivated hypothalamic AMPK in euthyroid rats. Our data indicated that stereotaxic delivery of a dominant-negative AMPKα (AMPKα-DN) 19 into the VMH increased malonyl-CoA concentrations in the ventral hypothalamus (Fig. 6a) and induced weight lost (Fig. 6b) independently of food intake ( Fig. 6c) and neuropeptide expression (Supplementary Fig. 7e ). AMPKα-DN promoted expression of thermogenic markers specifically in BAT ( Fig. 6d and Supplementary Fig. 7f,g ). Inhibition of β3-AR in BAT by subcutaneous administration of SR59230A (ref. 30 ) reversed AMPKα-DNinduced weight loss and blunted the mRNA expression of BAT thermogenic markers without altering food intake ( Fig. 6e-g ). 
DISCUSSION
This study identifies a homeostatic link between the effects of thyroid hormone on hypothalamic AMPK and activation of BAT by the SNS (Fig. 6h) . Hyperthyroidism is a metabolic state characterized by negative energy balance and decreased fat mass 1 . There is evidence that impaired expression or activity of enzymes involved in fatty acid metabolism in the hypothalamus is associated with changes in neuropeptide expression and corresponding changes in food intake 17, 19, 21, 22, 24, 26, 27, 33 . Thyroid hormones also modulate lipid metabolism in peripheral tissues 6, 7, 8, 15, [34] [35] [36] . Therefore, we hypothesized that hyperthyroidism-induced hyperphagia might be mediated by specific alterations in lipid metabolism in the hypothalamus 8, 14, 15 . Here we show that hyperthyroidism and T3 increase de novo lipogenesis specifically in the hypothalamus but not in other brain regions. These prolipogenic changes in the hypothalamus are mediated by decreased amounts and activity of AMPK, which results in activation of ACC and accumulation of malonyl-CoA 37, 38 . The pathophysiological relevance of the T3-mediated increase in hypothalamic lipid biosynthesis is notable, and we speculate that it represents an adaptive allostatic response that helps maintain appropriate levels of structural and signaling lipids in a hypermetabolic state. Alternatively, it might reflect an imbalance between lipid biosynthetic and pro-oxidative pathways [34] [35] [36] .
Our results indicate that hyperthyroidism induces a hyperphagic response that is accompanied by corresponding changes in the expression of orexigenic and anorexigenic neuropeptides in the hypothalamus. Of note, the decrease in Pomc expression was associated with decreased amounts of the transcription factors pFoxO1 and pSTAT3, which are known to regulate Pomc transcription 39, 40 . One of the more puzzling aspects of our data is the resilience of the hyperthyroidism-induced hyperphagia, which is resistant to the known anorectic effects of Thyroid hormone-induced changes in the hypothalamic lipid biosynthetic pathway increases levels of hypothalamic malonyl-CoA and complex lipids. These changes are associated with the activation of the SNS through the raphe pallidus and the inferior olive nuclei, resulting in increased expression of BAT markers, such as Ucp1, Upc3, Ppargc1a (which encodes PGC1α) and Ppargc1b (which encodes PGC1β), promoting negative energy balance and weight loss. *P < 0.05, **P < 0.01, ***P < 0.001 versus GFP; # P < 0.05, ## P < 0.01 AMPKα-DN vehicle versus AMPKα-DN SR59230A; all data are expressed as means ± s.e.m.
a r t i c l e s nature medicine VOLUME 16 | NUMBER 9 | SEPTEMBER 2010 1 0 0 7 malonyl-CoA accumulation and inactivation of CPT1 in the hypothalamus. This is observed even after treatment with cerulenin, which inhibits FAS and potentiates the increase in hypothalamic malonylCoA. Although the mechanisms by which this occurs are unclear, we speculate that accumulation of specific lipid species in the hypothalamus of hyperthyroid rats might have a role. Moreover, it is possible that, under conditions of elevated energy demand, specific allostatic responses might overrule the usual inhibition of energy intake by malonyl-CoA. In support of this, recent evidence shows that although hypothalamic fatty acid metabolism has a key role in mediating adaptive feeding responses to fasting 19, [21] [22] [23] 26, 41, 42 and acute administration of hormones [16] [17] [18] [19] [20] , its role in the long-term control of feeding is less clear 43 . One possibility is that changes in other lipid species, in addition to malonyl-CoA might interfere with the usual mechanisms controlling feeding. The main finding of our research is the fundamental role of T3 indirectly activating the thermogenic program in BAT via the CNS. Conventionally, this thyroid hormone-induced thermogenesis has been ascribed to the direct action of T3 on BAT and muscle [1] [2] [3] 5 . Given that thyroid hormones also exert major effects in the CNS 2 , we hypothesized that central T3 action might contribute to wholebody metabolism. In support of this, we demonstrate that genetic inhibition of TR in the VMH reverses the effects of hyperthyroidism on energy balance and the thermogenic program in BAT. Our results also indicate that hyperthyroidism alters hypothalamic AMPKdependent activation of de novo lipogenesis, which results in weight loss via increased energy dissipation in BAT. Conversely, inactivation of hypothalamic fatty acid metabolism reduces activation of BAT and prevents the weight loss associated with hyperthyroidism. To determine the physiological relevance of these observations, we investigated whether selective alteration of fatty acid metabolism in the VMH is sufficient to modulate BAT activity, a function for this hypothalamic nucleus that has been noted previously 5, [44] [45] [46] . We found here that inactivation of AMPK in the VMH activates thermogenesis in BAT through the SNS. Indeed, selective genetic inhibition of AMPK in the VMH induced weight loss and increased BAT activation without altering feeding. Moreover, the changes in mRNA expression in BAT and the decrease in body weight were reversed by treatment with the selective β3-AR antagonist SR59230A, indicating an essential role of the SNS in these effects. The precise mechanisms linking hypothalamic AMPK activity with sympathetic tone require further investigation. However, our evidence shows that central administration of T3 elicits a marked increase in neuronal activity, measured as c-Fos immunoreactive cells, in the raphe pallidus and the inferior olive, nuclei that receive output from the VMH to the intermediolateral neurons and the sympathetic chain, which ultimately innervates BAT 5 .
Although, classically, the VMH is considered to be a regulator of feeding control ('the satiety center'), recent evidence reveals a more complex physiological role. For example, AMPK in the VMH is involved in integrating peripheral signals such as ghrelin with the hypothalamic signaling network 19, 33 and in detecting acute hypoglycemia and mounting a counter regulatory glucose response 47 . Overall, these data indicate that AMPK acts in the VMH as a global energy gauge that modulates both food intake and the thermogenic program. Our data reveal a pathophysiological relevance of this homeostatic regulatory mechanism in the context of hyperthyroidism. Further studies are needed to determine whether this mechanism is restricted to the hyperthyroid state or whether it contributes to other pathological states characterized by negative energy balance (for example, cachexia or wasting diseases), as well as its physiological role in humans. In keeping with this, recent evidence highlights the key role of BAT in adult humans [48] [49] [50] [51] and that thyroid status affects BAT activity 52 . The role of AMPK activity and fatty acid metabolism in the hypothalamus in mediating thyroid hormone-induced thermogenesis, alongside other evidence demonstrating that targeting of hypothalamic AMPK, or of upstream kinases, affects energy homeostasis 16, 37, [53] [54] [55] [56] , indicates that selective modulation of AMPK activity in this region, more specifically in the VMH, might be a useful strategy to treat disorders that involve compromised energy balance, such as hyperthyroidism, cachexia and obesity. Additionally, our study indicates that strategies to modulate either AMPK or lipid abundance in the hypothalamus might be of therapeutic benefit in controlling the peripheral effects of thyrotoxicosis and life-threatening conditions, such as thyroid storm, for which current treatments are not satisfactory.
In summary, we show that hyperthyroidism inactivates AMPK, induces a marked upregulation of de novo lipogenesis specifically in the hypothalamus and activates the BAT via the SNS, leading to weight loss. Thus, our data indicate that dysregulation of fatty acid metabolism in the hypothalamus is a major effector of hyperthyroidisminduced negative energy balance through its effects on energy dissipation. This observation provides new insights into the pathogenesis of hyperthyroidism-induced effects on energy balance and suggests potential therapeutic strategies to counteract these effects in the context of this disorder or other catabolic states.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website. a r t i c l e s
